foresite capital  wikipedia foresite capital from wikipedia the free encyclopedia jump to navigation search foresite capital industry venture capital growth equity founded  founder jim tananbaum ceo website wwwforesitecapitalcom foresite capital is an american venture capital and growth equity firm the company has offices in san francisco and new york as of may  the company had raised three funds foresite capital fund i ii and iii historyedit foresite capital was founded in  by jim tananbaum cofounder of theravance who became ceo of the company foresite capital raised its  million fund i in  foresite has invested in companies such as epizyme intarcia therapeutics aerie pharmaceuticals muse bio and universal american foresite has funded x genomics since its series a round in november  and led its series b round in january  as well as its series c round in march  in april  foresite closed foresite capital fund ii a  million fund foresite capital fund iii a  million fund was closed in july  referencesedit  a b c david holley  july  foresite capital keeps latestage healthcare focus with m third fund xconomy retrieved  may    brian gormley  january  growthequity firm foresite capital raises m for debut healthcare fund wall street journal retrieved  may    damian garde  july  foresite capital reloads with a m biotech venture fund fierce biotech retrieved  may    foresite capital raises m to invest in latestage healthcare companies san francisco business times  january  retrieved  may    a b c eric blattberg  april  health care venture firm foresite capital closes m fund venture beat retrieved  may    ben fidler  november  karyopharm prices upsized ipo at  per share begins trading today xconomy retrieved  may    luke timmerman  january  foresite capital closes m fund for latestage biotechs xconomy retrieved  may    dan primack  september  diabetes ‘unicorn’ raises final vc round before ipo fortune retrieved  may    here’s who stands to gain from intarcia’s success with a type  diabetes pump boston business journal  october  retrieved  may    ed lin  october  aerie stock hits record high holder sells  million barrons retrieved  may    muse bio closes m series b financing round genome web retrieved  may    nick paul taylor  march  x genomics scoops another m to fuel commercialization of longread tech fierce biotech retrieved  may    alex lash  january  x genomics emerges with m and toastersized sequencer upgrade xconomy retrieved  may    a b damian gards  april  foresite banks m to bet on latestage biotechs fierce biotech retrieved  may   this article about a financial services corporation of the united states is a stub you can help wikipedia by expanding it v t e retrieved from httpsenwikipediaorgwindexphptitleforesitecapitaloldid categories venture capital firms of the united statesamerican companies established in united states financial services company stubshidden categories all stub articles navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  may  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view team  foresite capital strategy portfolio about team news contact our team investment team specifically constructed to identify evaluate and fund what we believe are the best opportunities in healthcare each member of our team brings a diverse and complementary set of skills experience and networks to help accelerate company growth foresite’s principals draw on their track record of developing and launching revolutionary healthcare products and leading financings with successful outcomes alvin tam trading operations manager brett zbar managing director collin yangwong investment analyst dennis d ryan cfo  managing director dorothy margolskee managing director james klinect quantitative analyst jim tananbaum ceo  managing director luke bagaason investment analyst matthew buten managing director michael rome senior analyst molly he venture partner noah dennis investment analyst phil kallos director of engineering rhonda kaufman director richard lau senior investment analyst spencer knight data scientist stephen c peterson senior investment analyst tony wiemelt associate director michael rome  foresite capital strategy portfolio about team news contact our team alvin tam brett zbar collin yangwong dennis ryan dorothy margolskee james klinect jim tananbaum luke bagaason matthew buten michael rome molly he noah dennis phil kallos rhonda kaufman richard lau spencer knight stephen peterson tony wiemelt michael rome phd senior analyst highlights experience in both smallmidcap healthcare investing and early stage drug development authoredcoauthored high profile scientific papers including pnas cell and nature smb and a selected speaker at scientific conferences  years of experience as a biomedical scientist in biochemistry microbiology and neurobiology research laboratories michael joined foresite capital in  and previously was an equity analyst at dafna capital management a longshort healthcare hedge fund michael has experience investing across diverse therapeutic areas including oncology autoimmune and rare diseases previously he was scientist and senior scientist at vault pharma inc and worked in early stage drug development business development and ip portfolio management he received his phd in biochemistry from caltech where he was awarded an nsf graduate research fellowship and bs in molecular cell and developmental biology from ucla he has over  years of experience as a research scientist and has authored numerous publications in toptier biomedical research journals alvin tam brett zbar collin yangwong dennis ryan dorothy margolskee james klinect jim tananbaum luke bagaason matthew buten michael rome molly he noah dennis phil kallos rhonda kaufman richard lau spencer knight stephen peterson tony wiemelt richard lau  foresite capital strategy portfolio about team news contact our team alvin tam brett zbar collin yangwong dennis ryan dorothy margolskee james klinect jim tananbaum luke bagaason matthew buten michael rome molly he noah dennis phil kallos rhonda kaufman richard lau spencer knight stephen peterson tony wiemelt richard lau cfa senior investment analyst highlights more than  years of experience in healthcare research and investing across multiple subsectors including biotechnology specialty pharmaceuticals diagnostics and medical devices cfa charterholder and a member of both the cfa institute and the cfa society of san francisco earned ba in molecular and cell biology with a concentration in biochemistry from uc berkeley richard joined foresite capital in  and is a member of the investment team focusing on due diligence and financial modeling of investment opportunities  previously richard was an equity research analyst covering the specialty pharmaceutical sector at wedbush pacgrow life sciences a sellside research firm in this role he worked closely with companies seeking capital to fund their next stage of growth he began his career at pacific growth equities and assumed roles of increasing responsibility starting as an equity research associate and ending as a senior analyst covering the biotechnology sector richard received a ba in molecular and cell biology with a concentration in biochemistry from the university of california berkeley he is a cfa charterholder and a member of both the cfa institute and the cfa society of san francisco with a background in both the sciences and finance richard brings a balanced view to investing  alvin tam brett zbar collin yangwong dennis ryan dorothy margolskee james klinect jim tananbaum luke bagaason matthew buten michael rome molly he noah dennis phil kallos rhonda kaufman richard lau spencer knight stephen peterson tony wiemelt foresite capital strategy portfolio about team news contact helping build healthcare leaders we provide capital and support to help companies with transformative products and services become healthcare leaders scaling innovation through close collaboration with visionary entrepreneurs and a relentless focus on innovation and building value we aim to dramatically enhance patient care portfolio developing therapeutic antibodies to maximize efficacyprotecting people from food allergensaddressing glaucoma with tripleaction eyedropschanging the definition of sequencingreversing tumors associated with immunosuppressionrevolutionizing type  diabetes and obesity see full portfolio accelerating growth since our inception in  our strategy has been to offer complete capital solutions to help build categorydefining companies across therapeutics devices diagnostics and healthcare services b assets under management  funds closed  diverse team members news apr  prepare for the digital health revolution apr  foresite capital ceo jim tananbaum featured on the forbes midas list for the third year in a row apr  foresite capital announces ceo jim tananbaum named to forbes’ midas list  apr  adaptimmune raises m for pipeline work kalobios chief says biotech is on track for chagas drug filing see all news insider trading  foresite capital fund iii lp  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  foresite capital fund iii lp select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing salea  pm aerie pharmaceuticals inc aeri foresite capital management ii llcforesite capital fund ii lpforesite capital management iii llcforesite capital fund iii lptananbaum james b owner    indirect view sale  pm aerie pharmaceuticals inc aeri foresite capital management ii llcforesite capital fund ii lpforesite capital management iii llcforesite capital fund iii lptananbaum james b owner    indirect view purchase  am aerie pharmaceuticals inc aeri foresite capital management ii llcforesite capital fund ii lpforesite capital management iii llcforesite capital fund iii lptananbaum james b owner    indirect view sale  pm aimmune therapeutics inc aimt foresite capital management ii llcforesite capital fund ii lpforesite capital management iii llcforesite capital fund iii lptananbaum james b owner    indirect view purchase  pm aimmune therapeutics inc aimt foresite capital management ii llcforesite capital fund ii lpforesite capital management iii llcforesite capital fund iii lptananbaum james b owner    indirect view purchase  am aimmune therapeutics inc aimt foresite capital management ii llcforesite capital fund ii lpforesite capital management iii llcforesite capital fund iii lptananbaum james b owner    indirect view a indicate amendment filing stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing conversion  am nana aimmune therapeutics inc aimt foresite capital management ii llcforesite capital fund ii lpforesite capital management iii llcforesite capital fund iii lptananbaum james b owner   indirect view conversion  am nana aimmune therapeutics inc aimt foresite capital management ii llcforesite capital fund ii lpforesite capital management iii llcforesite capital fund iii lptananbaum james b owner   indirect view   secformcom all rights reserved archives        fri  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version strategy  foresite capital strategy portfolio about team news contact strategy our focus we are a trusted financial partner with a structure that allows us to partner with portfolio company management to develop complete financing solutions in both private and public markets ​​​​​​ we invest in emerging leaders across all areas of healthcare including therapeutics medical devices diagnostics and services our focus is on the development and commercialization of transformative products that address what we believe are the most critical unmet healthcare needs how were different we are a financial partner at all stages – venture and postventure private and public – partnering at the point where we believe we can make the biggest impact we function as a team participating together in primary diligence and sharing collective ownership of our investment and portfolio management decisions our collaborative team culture allows us to bring an array of unique perspectives and evaluate situations efficiently and effectively we provide a depth and breadth of insights and best practices from our experience with hundreds of companies to each of our ventures we have powerful highquality networks and deep experience across areas of healthcare including marketing sales business development research and development regulatory policy and communications the healthcare sector is experiencing unprecedented innovation driven by understanding vast amounts of biologic and genetic information a change we believe is leading to some of the most impactful medical solutions in decades innovation is increasingly focused on improving care and reducing costs our passion is to use our capital and networks to help build transformative healthcare companies and build a portfolio of companies that significantly impact the quality and effectiveness of the us healthcare system jim tananbaum ceo  managing director contact us  foresite capital strategy portfolio about team news contact contact us email us your name your email your number your comment sf  montgomery street suite  san francisco ca  tel    ny  avenue of the americas rd floor new york ny  tel    luke bagaason  foresite capital strategy portfolio about team news contact our team alvin tam brett zbar collin yangwong dennis ryan dorothy margolskee james klinect jim tananbaum luke bagaason matthew buten michael rome molly he noah dennis phil kallos rhonda kaufman richard lau spencer knight stephen peterson tony wiemelt luke bagaason cfa investment analyst highlights luke is a member of the cfa institute and the cfa society of colorado luke became a cfa charterholder in    luke graduated from the university of denver with a master’s of finance in  and earned his bachelor’s degree in business administration from the university of colorado at boulder in  luke bagaason is a member of the investment team at foresite capital with more than nine years of experience in the investment industry   prior to joining foresite capital fulltime in  luke ran his own registered investment advisory and offered asset management and consulting services to investment firms and high net worth individuals luke started his career as a registered representative with jp morgan asset management alvin tam brett zbar collin yangwong dennis ryan dorothy margolskee james klinect jim tananbaum luke bagaason matthew buten michael rome molly he noah dennis phil kallos rhonda kaufman richard lau spencer knight stephen peterson tony wiemelt jim tananbaum  foresite capital strategy portfolio about team news contact our team alvin tam brett zbar collin yangwong dennis ryan dorothy margolskee james klinect jim tananbaum luke bagaason matthew buten michael rome molly he noah dennis phil kallos rhonda kaufman richard lau spencer knight stephen peterson tony wiemelt jim tananbaum ceo  managing director highlights founded foresite capital in  cofounded geltex which was acquired for  billion by sanofigenzyme cofounded theravance inc total market cap of b which subsequently changed its name to innoviva inc nasdaq inva and with its spinoff theravance biopharma inc nasdaq tbph the companies have a combined market capitalization of  billion earned bs and bsee from yale university in applied math and computer science and ms from mit md and mba from harvard university member of yale’s university council and the advisory committee of the yale school of engineering  applied science    midas list jim is the founder of foresite capital and an industry leader with  years of healthcare entrepreneurial and investing experience jim focuses on strategic operational and financial opportunities to build franchise healthcare businesses he has been the chief architect of foresite capital’s investment organization structure and investment strategy and has played a significant role in numerous foresite capital portfolio companies prior to founding foresite capital jim cofounded two leading biopharmaceutical companies and two healthcare investment practices while finishing harvard university  medical and business schools and earning an ms from the massachusetts institute of technology mit he founded geltex pharmaceuticals nasdaqgenz which brought two drugs to market for less than  million geltex was acquired in  for  billion when its lead drug renagel renzela had an annual revenue run rate in excess of  million today renzela is estimated to produce close to  billion in annual revenue  years after its launch jim also cofounded and was ceo of theravance inc who share gsk’s respiratory franchise through a joint venture innoviva nasdaq inva and completed a spinoff theravance biopharma inc nasdaq tbph  the two companies have a combined market capitalization of approximately  billion jim’s investment experience includes being a founding partner of prospect venture partners ii and iii and earlier in his career  a partner at sierra ventures where he helped establish its healthcare services investment practice jim has led numerous investments including amira pharmaceuticals acquired by nyse bms amerigroup nasdaq amgp healtheon nasdaqwbmd and jazz pharmaceuticals nasdaq jazz  jim founded foresite capital with the vision of marrying elements of all aspects of his career to create a novel investment platformjim graduated with a bs and bsee from yale university an md from harvard medical school an ms from mit and an mba from harvard business school he has served on the advisory boards and visiting committees to the harvardmit hst program and on yale’s president advisory counsel alvin tam brett zbar collin yangwong dennis ryan dorothy margolskee james klinect jim tananbaum luke bagaason matthew buten michael rome molly he noah dennis phil kallos rhonda kaufman richard lau spencer knight stephen peterson tony wiemelt about us  foresite capital strategy portfolio about team news contact about foresite what we do we provide growth capital to emerging healthcare leaders with disruptive products and services with the goal of transforming patient care foresite capital typically invests small amounts in its initial investment in a portfolio company  million can invest in private and public securities and can invest significant capital over time   million into portfolio company securities foresite capital’s goal is to help portfolio companies grow from proofofconcept to revenue growth and profitability foresite capital provides strategic insight creativity drive and networks of highvalue professionals in addition to capital to its portfolio companies   we built foresite with a deep multidisciplinary and highly experienced team in order to optimize sourcing evaluation and growth acceleration with more than b in assets under management as of june  we apply insight creativity and drive to earn the trust of our portfolio companies how we work our investment team possesses more than  years of collective experience in the healthcare and investment industries we believe this broad and deep experience has produced a bestinclass network of contacts to help our portfolio companies accelerate growth internally our team functions collaboratively with each member of the team participating at all stages of the investment process foresite capital’s due diligence and decisionmaking process is structured to understand and help portfolio companies mitigate key technical regulatory execution and competitive risks rhonda kaufman  foresite capital strategy portfolio about team news contact our team alvin tam brett zbar collin yangwong dennis ryan dorothy margolskee james klinect jim tananbaum luke bagaason matthew buten michael rome molly he noah dennis phil kallos rhonda kaufman richard lau spencer knight stephen peterson tony wiemelt rhonda kaufman md director highlights rhonda has more than  years of healthcare industry experience she is a board certified internist and clinical pharmacologist with extensive pharmaceutical industry experience  rhondas expertise in drug development ranges across translational medicine clinical pharmacology business development and outcomes research additionally she has had executivelevel experience in the managed care industry at foresite capital she is a member of the investment team and contributes to due diligence and evaluation of companiesmost recently rhonda joined foresite capital after a year career at merck research laboratories where she was a vice president during her tenure at merck she helped establish several departments including experimental medicine regional deals in business development emerging markets research and development and outcomes researchafter graduating from boston university rhonda completed her internship and residency in internal medicine at the boston veterans administration hospital boston ma rhonda later completed a fellowship in clinical pharmacology and a clinical investigator training program at tuftsharvardmit division of health sciences and technology rhonda is a diplomate in the american board of internal medicine and the american board of clinical pharmacology and maintains an active medical license in the commonwealth of massachusetts alvin tam brett zbar collin yangwong dennis ryan dorothy margolskee james klinect jim tananbaum luke bagaason matthew buten michael rome molly he noah dennis phil kallos rhonda kaufman richard lau spencer knight stephen peterson tony wiemelt tony wiemelt  foresite capital strategy portfolio about team news contact our team alvin tam brett zbar collin yangwong dennis ryan dorothy margolskee james klinect jim tananbaum luke bagaason matthew buten michael rome molly he noah dennis phil kallos rhonda kaufman richard lau spencer knight stephen peterson tony wiemelt tony wiemelt phd associate director highlights implemented  programs integrating pharmacogenomics and cuttingedge precision medicine technology into daily practice at penn medicine orchestrated executive management of merck’s oncology and infectious disease franchises developed and helped implement merck’s rd sharepoint it platform improving information flow accountability and project tracking throughout the organization tony has worked in the pharmaceuticalhealthcare industry for more than  years as a project and portfolio management leader at foresite capital he is a member of the investment team and focuses on company research and due diligence  he joined foresite capital from university of pennsylvania health system where he was the chief administrative officer for precision medicine while at penn tony developed and implemented detailed business plans for strategic programmatic and operational aspects of penn medicine’s precision medicine program across multiple clinical areas including oncology cardiovascular obgyn and neurologyprior to penn tony worked at merck research laboratories across multiple therapeutic areas and was the projectportfolio manager for development projects across all phases of development within global project management tony held positions as director infectious disease portfolio as well as the director oncology portfolio two of merck’s key franchises in addition tony was responsible for coordinating project management of the scientific due diligence for all potential licensing candidates for merck research laboratories  tony received his phd in neuroscience from the university of pennsylvania his research focused on the role of second messenger systems cyclic amp in the regulation of development of neural supportive tissues oligodendrocytes he completed his postdoctoral fellowship at the department of cell  molecular biology university of pennsylvania where he explored zebrafish neural development and the role of bone morphogenetic proteins in the specification of neural tissues and mechanisms of gene action in early neural patterning alvin tam brett zbar collin yangwong dennis ryan dorothy margolskee james klinect jim tananbaum luke bagaason matthew buten michael rome molly he noah dennis phil kallos rhonda kaufman richard lau spencer knight stephen peterson tony wiemelt team  foresite capital strategy portfolio about team news contact our team investment team specifically constructed to identify evaluate and fund what we believe are the best opportunities in healthcare each member of our team brings a diverse and complementary set of skills experience and networks to help accelerate company growth foresite’s principals draw on their track record of developing and launching revolutionary healthcare products and leading financings with successful outcomes alvin tam trading operations manager brett zbar managing director collin yangwong investment analyst dennis d ryan cfo  managing director dorothy margolskee managing director james klinect quantitative analyst jim tananbaum ceo  managing director luke bagaason investment analyst matthew buten managing director michael rome senior analyst molly he venture partner noah dennis investment analyst phil kallos director of engineering rhonda kaufman director richard lau senior investment analyst spencer knight data scientist stephen c peterson senior investment analyst tony wiemelt associate director portfolio  foresite capital strategy portfolio about team news contact portfolio featured companies revolutionizing type  diabetes and obesityintarcias device is a matchsticksized osmotic pump that delivers glp glucagonlike peptide in a manner that avoids the need for regular painful injections while producing efficacy and tolerability resultsprotecting people from food allergensaimmune’s characterized oral desensitization immunotherapy codit™ system combines proprietary product candidates with gradual controlled updosing protocols to obtain meaningful desensitization to food allergens changing the definition of sequencingwith the gemcode platform x genomics researchers can now find structural variants haplotypes and other valuable long range information while leveraging existing sequencing workflowsaddressing glaucoma with tripleaction eyedropsaerie is developing firstinclass oncedaily eye drops with the ability to reduce intraocular pressure iop in patients with openangle glaucoma and ocular hypertensionreversing tumors associated with immunosuppressionarcus is pursuing smallmolecule and proteinbased therapeutics to block active immunosuppression pathways and selectively stimulate the tumorkilling activity of effector immune cellsdeveloping therapeutic antibodies to maximize efficacyalders ald is a novel monoclonal antibody targeting calcitonin generelated peptide cgrp in phase  trials for the prevention of migraine headaches full portfolio  any biopharmaceuticalbiotechnologydrugdevice combinations and medical devicesgenomics tools and data sciencehealthcare services and data sciencepharmaceuticals aerie pharmaceuticals nasdaqaeri stock price news  analysis aerie pharmaceuticals company profile nasdaqaeri company profile analyst ratings earnings history earnings estimates dividend history insider trade headlines social media chart about aerie pharmaceuticals nasdaqaeri aerie pharmaceuticals inc is a clinicalstage pharmaceutical company the company is engaged in the discovery development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye the companys product candidates include rhopressa netarsudil ophthalmic solution  rhopressa and roclatan netarsudillatanoprost ophthalmic solution  roclatan the companys product candidates are designed to lower intraocular pressure iop in patients with openangle glaucoma and ocular hypertension its rhopressa is a oncedaily eye drop rhopressa inhibits rho kinase rock and the norepinephrine transporter net which are both biochemical targets for lowering iop its roclatan is a oncedaily fixeddose combination of rhopressa and latanoprost which is a prescribed drug for the treatment of patients with openangle glaucoma the company is engaged in conducting phase iii clinical trial for roclatan industry sector and symbol sector medical industry bio therapeutic drugs subindustry na symbol nasdaqaeri cusip na web wwwaeriepharmacom capitalizationmarket cap  billionoutstanding shares average prices day moving avg  day moving avg  week range    petrailing pe ratio naforeward pe ratio pe growth sales  book valueannual revenue naprice  sales nabook value  per shareprice  book  profitabilityebidta return on equity return on assets debtdebttoequity ratio current ratio quick ratio miscaverage volume  shsbeta short ratio    frequently asked questions for aerie pharmaceuticals nasdaqaeri what is aerie pharmaceuticals stock symbol aerie pharmaceuticals trades on the nasdaq under the ticker symbol aeri how were aerie pharmaceuticals earnings last quarter aerie pharmaceuticals inc nasdaqaeri announced its quarterly earnings data on tuesday may nd the company reported  earnings per share eps for the quarter missing analysts consensus estimates of  by  view aerie pharmaceuticals earnings history when will aerie pharmaceuticals make its next earnings announcement aerie pharmaceuticals is scheduled to release their next quarterly earnings announcement on tuesday august st  view earnings estimates for aerie pharmaceuticals where is aerie pharmaceuticals stock going where will aerie pharmaceuticals stock price be in   analysts have issued  month price objectives for aerie pharmaceuticals shares their predictions range from  to  on average they expect aerie pharmaceuticals share price to reach  in the next twelve months view analyst ratings for aerie pharmaceuticals what are analysts saying about aerie pharmaceuticals stock here are some recent quotes from research analysts about aerie pharmaceuticals stock  according to zacks investment research aerie’s efforts on developing two latestage candidates – rhopressa and roclatan – are encouraging the company resubmitted new drug application nda for lead candidate rhopressa in feb  the fda determined that the application is sufficiently complete to permit a substantive review and set the pdufa goal date for the completion of review as feb   aerie had earlier withdrawn its nda that was filed in september as a third party manufacturing facility in tampa fl was not ready for preapproval inspection by the fda a potential approval and successful commercialization will significantly boost the company’s growth prospects in the global ophthalmic market the recent data on roclatan is also positive moreover aerie’s shares have outperformed the industry in the year so far however with no approved product in its portfolio aerie depends heavily on a potential approval of rhopressa   hc wainwright analysts commented blueprint reported a q net loss of mm and ended the quarter with mm   aegis analysts commented we still consider the upcoming mercury  threemonth efficacy readout for roclatan expected before the end of q  as being a potentially share moving event higher patients dropout rate seen in rhopressa arm relative to timolol arm is not concerning to us  of the patients in the rhopressa arm of the trial discontinued treatment by month  compared to  of the patient population in the timolol arm the most common reason for discontinuation seen in the rhopressa arm was related to adverse events at about    of the subjects in the timolol arm dropped out due to adverse events as a point of reference given that  of patients  out of  patients on rhopressa qd completed the treatment by month  in rocket  we estimate a maximum dropoff rate of rhopressa at  further according to results published in persistency a new take on patient care by schwartz in review of ophthalmology    the discontinuation rates of  for latanoprosttravoprostbimatoprost were seen at month  and  with rates increasing to  respectively at month    needham  company llc analysts commented  aeri reported q financials and updated ongoing rhopressa and roclatan development activities the rhopressa nda was refiled in late feb following an issue at the third party manufacturer aeri expects a potential pdufa in q after a standard fda review and is in the process of building a commercial org in anticipation of a h product launch key data from both rhopressa and roclatan are expected in q topline safety data from the ph  rocket trial and topline efficacy data from the ph  mercury trial aeri expects to file an nda for roclatan in late early  we maintain our buy rating and slightly adjust our pt to  from  to reflect a model and valuation update   brean capital analysts commented at yesterday’s investor day aerie painted a clearer portrait of the current standard of care and competitive glaucoma treatment environment management also provided further insight into the recent mercury  data for roclatan a closer look at how to measure the effectiveness of glaucoma treatment with added perspective from a former physician as well as revisited what the company’s future value adding drivers will be and articulated the international strategy we took the opportunity to dive deeper into our model taking into account potential future european launches and japanese clinical trials  who are some of aerie pharmaceuticals key competitors some companies that are related to aerie pharmaceuticals include intercept pharmaceuticals icpt juno therapeutics juno gw pharmaceuticals plc gwph beigene bgne ultragenyx pharmaceutical rare agios pharmaceuticals agio china biologic products cbpo avexis avxs axovant sciences axon prothena corporation plc prta sarepta therapeutics srpt spark therapeutics once loxo oncology loxo radius health rdus novocure limited nvcr lexicon pharmaceuticals lxrx halozyme therapeutics halo and array biopharma arry who are aerie pharmaceuticals key executives aerie pharmaceuticals management team includes the folowing people vicente anido jr phd chairman of the board chief executive officerthomas a mitro president chief operating officercasey c kopczynski phd cofounder chief scientific officerrichard j rubino cpa chief financial officer secretarygerald d cagle phd independent directorrichard j croarkin independent directormichael m du toit independent directormurray a goldberg independent directorbenjamin f mcgraw iii pharmd independent director who owns aerie pharmaceuticals stock aerie pharmaceuticals stock is owned by many different of institutional and retail investors top institutional investors include russell investments group ltd  suffolk capital management llc  handelsbanken fonder ab  handelsinvest investeringsforvaltning  legato capital management llc  and harvey capital management inc  company insiders that own aerie pharmaceuticals stock include foresite capital fund ii lp geoffrey m duyk and gerald d cagle view institutional ownership trends for aerie pharmaceuticals who sold aerie pharmaceuticals stock who is selling aerie pharmaceuticals stock aerie pharmaceuticals stock was sold by a variety of institutional investors in the last quarter including harvey capital management inc and creative planning company insiders that have sold aerie pharmaceuticals stock in the last year include foresite capital fund ii lp and geoffrey m duyk view insider buying and selling for aerie pharmaceuticals who bought aerie pharmaceuticals stock who is buying aerie pharmaceuticals stock aerie pharmaceuticals stock was acquired by a variety of institutional investors in the last quarter including russell investments group ltd suffolk capital management llc handelsbanken fonder ab handelsinvest investeringsforvaltning legato capital management llc fox run management llc and aperio group llc company insiders that have bought aerie pharmaceuticals stock in the last two years include foresite capital fund ii lp and gerald d cagle view insider buying and selling for aerie pharmaceuticals how do i buy aerie pharmaceuticals stock shares of aerie pharmaceuticals can be purchased through any online brokerage account popular online brokerages include vanguard brokerage services td ameritrade etrade scottrade fidelity and charles schwab what is aerie pharmaceuticals stock price today one share of aerie pharmaceuticals stock can currently be purchased for approximately  marketbeat community rating for aerie pharmaceuticals nasdaq aericommunity ranking   out of     outperform votes   vote outperformunderperform votes   vote underperformtotal votes  marketbeats community ratings are surveys of what our community members think about aerie pharmaceuticals and other stocks vote outperform if you believe the stock will outperform the sp  over the long term vote underperform if you believe the stock will underperform the sp  over the long term you may vote once every thirty days analyst ratings consensus ratings for aerie pharmaceuticals nasdaqaeri how are consensus ratings calculated marketbeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months since brokers often use different ratings systems each rating is normalized to a standardized rating score of  sell  hold  buy or  strong buy consensus ratings scores are calculated using the mean average of the number of normalized sell hold buy and strong buy ratings each stocks consensus rating is derived from its calculated consensus ratings score   sell   hold   buy   strong buy marketbeats consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve monthsmarketbeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and marketbeat has received a report that coverage was dropped ratings from certain research firms that issue ratings using purely quantitative methods such as zacks vetr and valuengine are not included in consensus calculations marketbeats consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available dataratings breakdown  hold rating  buy ratingsconsensus ratingbuy score consensus price target   upside analysts ratings history for aerie pharmaceuticals nasdaqaeri show only the most recent rating from each brokerage all ratings for this stock datefirmactionratingprice targetimpact on share pricedetailsstifel nicolausreiterated ratingbuymediumcantor fitzgeraldreiterated ratingoverweight  overweight  highcanaccord genuityreiterated ratingbuymediumcowen and companyset price targetbuynaaegisboost price targetbuy  highhc wainwrightreiterated ratingbuyhighneedham  company llcboost price targetbuy  buy  highjmp securitiesreiterated ratingoutperformlowraymond james financial incdowngradestrongbuy  market performlowroyal bank of canadaboost price targetoutperform  mediumroth capitalinitiated coveragebuynabrean capitalreiterated ratingbuy  nadata available from  forward earnings earnings history for aerie pharmaceuticals nasdaqaeriearnings history by quarter for aerie pharmaceuticals nasdaq aeridatequarterconsensus estimateactual epsrevenue estimateactual revenuerelease linkconference calldetailsnaq viewlistenq viewlistenqviewnaqviewnaqviewnaqviewnaqviewnaqviewnaq viewlistenqviewnaq viewnaq viewnaq viewnaqviewnaqviewnadata available from  forward estimates earnings estimates for aerie pharmaceuticals nasdaqaericurrent year eps consensus estimate  epsnext year eps consensus estimate  eps dividends dividend history for aerie pharmaceuticals nasdaqaerino dividend announcements for this company have been tracked by marketbeatcom insider trades insider trading and institutional ownership history for aerie pharmaceuticals nasdaqaeriinsider ownership percentage institutional ownership percentage insider trades by quarter for aerie pharmaceuticals nasdaqaeritransaction dateinsider nametitlebuysellnumber of sharesaverage share pricetotal transactiondetailsforesite capital fund ii lpmajor shareholdersell  gerald d cagledirectorbuy  geoffrey m duykdirectorsell  foresite capital fund ii lpmajor shareholdersell  foresite capital fund ii lpmajor shareholderbuy  anand mehradirectorsell  lifesciences ii lp clarusmajor shareholdersell  lifesciences ii lp clarusmajor shareholdersell  lifesciences ii lp clarusmajor shareholdersell  lifesciences ii lp clarusmajor shareholdersell  lifesciences ii lp clarusmajor shareholdersell  anand mehradirectorsell  group holdings sbs advis tpginsidersell  group holdings sbs advis tpgmajor shareholdersell  group holdings sbs advis tpgmajor shareholdersell  anand mehradirectorsell  iv lp acpmajor shareholdersell  gerald cagledirectorbuy  brian levyinsiderbuy  iv lp acpmajor shareholderbuy  richard j rubinocfobuy  thomas a mitrocoobuy  vicente anido jrceobuy  anand mehradirectorbuy  lifesciences ii lp clarusmajor shareholderbuy  data available from  forward headlines headline trends for aerie pharmaceuticals nasdaqaeri latest headlines for aerie pharmaceuticals nasdaqaeri source all sources trusted sources marketbeatcom bloomberg marketwatch motley fool nasdaq reuters seeking alpha the street the wall street journal yahoo finance dateheadlinewhats in the cards for aerie aeri this earnings seasonfinanceyahoocom  july  at  pmaerie pharmaceuticals to announce second quarter  financial results and host conference call on tuesday   business wire press releasewwwbusinesswirecom  july  at  amaerie pharmaceuticals to announce second quarter  financial results and host conference call on tuesday august  financeyahoocom  july  at  pmaerie pharmaceuticals inc nasdaqaeri given consensus rating of buy by brokerageswwwamericanbankingnewscom  july  at  pmaerie pharmaceuticals announces appointment of richard a halprin as director of professional affairs  business wire press releasewwwbusinesswirecom  july  at  pmaerie pharmaceuticals inc aeri to release earnings on tuesdaywwwamericanbankingnewscom  july  at  amzacks brokerages expect aerie pharmaceuticals inc aeri to post  epswwwamericanbankingnewscom  july  at  amdiabetic macular edema pipeline therapeutics companies and drugs profile insights  available at rnr market   pr newswire press releasewwwprnewswirecom  july  at  pmaerie pharmaceuticals inc nasdaqaeri to post fy earnings of  per share cantor fitzgerald forecastswwwamericanbankingnewscom  july  at  amcommit to purchase aerie pharmaceuticals at  earn  using options  nasdaqwwwnasdaqcom  july  at  pminsmed insm versus aerie pharmaceuticals aeri head to head surveywwwamericanbankingnewscom  july  at  pmbriefaerie pharmaceuticals reports positive roclatan phase  month topline safety resultswwwreuterscom  july  at  amaerie pharmaceuticals inc nasdaqaeri price target raised to  at cantor fitzgeraldwwwamericanbankingnewscom  july  at  pmaerie pharmas eye drop roclatan safe in month study  seeking alphaseekingalphacom  july  at  pmbriefbrian grossman reports  pct passive stake in aerie pharmaceuticals inc as of july   sec filingwwwreuterscom  july  at  pmaerie pharmaceuticals inc nasdaqaeri downgraded by zacks investment research to holdwwwamericanbankingnewscom  july  at  pminotek to explore strategic options after eye drug fails trial  reuterswwwreuterscom  july  at  pminotek to explore strategic options after eye drug fails trialwwwreuterscom  july  at  amaerie pharmaceuticals inc nasdaqaeri earns buy rating from canaccord genuitywwwamericanbankingnewscom  july  at  amaerie pharmaceuticals inc aeri receives average rating of buy from analystswwwamericanbankingnewscom  june  at  pm brokerages expect aerie pharmaceuticals inc aeri will announce earnings of  per sharewwwamericanbankingnewscom  june  at  pmbidaskclub lowers aerie pharmaceuticals inc aeri to strong sellwwwamericanbankingnewscom  june  at  pmcan the uptrend continue for aerie pharmaceuticals aeri  nasdaqwwwnasdaqcom  june  at  pmaerie pharmaceuticals inc aeri given consensus rating of buy by analystswwwamericanbankingnewscom  june  at  amzacks brokerages anticipate aerie pharmaceuticals inc aeri will post earnings of  per sharewwwamericanbankingnewscom  june  at  pmaerie pharmaceuticals inc aeri major shareholder foresite capital fund ii lp sells  shareswwwamericanbankingnewscom  may  at  pmive joined aerie pharmaceuticals in selling its stock  seeking alphaseekingalphacom  may  at  pmaerie pharmaceuticals aeri buy rating reiterated at stifel nicolauswwwamericanbankingnewscom  may  at  pmaerie pharmaceuticals inc aeri given a  price target by cowen and company analystswwwamericanbankingnewscom  may  at  amaerie pharmaceuticals raises  million in atm sales and upsized followon offering  business wire press releasewwwbusinesswirecom  may  at  pmaerie pharmaceuticals raises  million in atm sales and upsized followon offeringfinanceyahoocom  may  at  pmbiocryst and aerie pharmaceuticals shares swell on positive study resultsfinanceyahoocom  may  at  pmpharma stock roundup label expansion for merck drug aerie up on eye datafinanceyahoocom  may  at  pmbiotech movers immunomedics aerie exelixisfinanceyahoocom  may  at  pmbriefaerie pharma to offer common shares in public offeringwwwreuterscom  may  at  amaegis reaffirms buy rating for aerie pharmaceuticals inc aeriwwwamericanbankingnewscom  may  at  amaerie pharmaceuticals inc aeri given outperform rating at cowen and companywwwamericanbankingnewscom  may  at  ambriefaerie pharmaceuticals enters into controlled equity offering sales agreement with cantor fitzgerald  reuterswwwreuterscom  may  at  pmaerie pharma stock surges  on positive latestage trial results for glaucoma eye drops  marketwatchwwwmarketwatchcom  may  at  pmwhy aerie pharmaceuticals inc is skyrocketing today  motley foolwwwfoolcom  may  at  pmaerie pharmaceuticals inc aeri given a  price target at hc wainwrightwwwamericanbankingnewscom  may  at  pmaerie pharmaceuticals inc aeri given a  price target at cantor fitzgeraldwwwamericanbankingnewscom  may  at  pmbriefaerie pharmas roclatan succeeds in second latestage studywwwreuterscom  may  at  pmaerie pharmaceuticals aeri updates on roclatan mercury phase  topline efficacy results  slideshowseekingalphacom  may  at  pmhas aerie pharma put the binary boogeyman to bed with roclatan phase  datafeedsbenzingacom  may  at  pmwhy aerie pharmaceuticals inc is skyrocketing todaywwwfoolcom  may  at  pmneedham  company llc boosts aerie pharmaceuticals inc aeri price target to wwwamericanbankingnewscom  may  at  amaerie pharmaceuticals reports positive roclatan™ netarsudillatanoprost ophthalmic solution  phase   business wire press releasewwwbusinesswirecom  may  at  amaerie pharmaceuticals inc aeri is surging on phase  study resultswwwrttnewscom  may  at  pmaerie pharmaceuticals reports positive roclatan™ netarsudillatanoprost ophthalmic solution  phase  topline efficacy resultsfinanceyahoocom  may  at  pm social chart aerie pharmaceuticals aeri chart for friday july   this page was last updated on  by marketbeatcom staff jim tananbaum  foresite capital   stock picks and performance  insider monkey companies  see all hedge funds  see all insiders  see all institutional investors  see all click here to see all results for sorry no results has been found matching your query adblocker detected dear valued visitor we have noticed that you are using an ad blocker software although advertisements on the web pages may degrade your experience our business certainly depends on them and we can only keep providing you highquality research based articles as long as we can display ads on our pages to view this article you can disable your ad blocker and refresh this page or simply login we only allow registered users to use ad blockers you can sign up for free by clicking here or you can login if you are already a member home  hedge funds  foresite capital  profile hedge fund  foresite capital get email alerts profile holdings latest d  g filings news interviews and investor letters get email alerts profile holdings latest d  g filing news jim tananbaum bio returns net worth manager biography is currently missing fund profile filing period                            fund name foresite capital manager jim tananbaum portfolio value  change this qtr  top holdings login to see all holdings  sign up filing period                            no security ticker shares value x activity  port  acceleron pharma inc xlrn     biodelivery sciences intl inc bdsi     orexigen therapeutics inc orex    login to see all holdings  sign up its free news interviews and investor letters see all g filing foresite capital fund iii lp and verona pharma plc vrna sole voting power ordinary shares “shares” represented by  american depositary shares “adss” except that foresite capital management iii llc “fcm iii” the general read more may th   hedge funds  comments g filing foresite capital fund iii lp and tocagen inc toca sole voting power shares except that foresite capital management iii llc “fcm iii” the general partner of fcf iii may be deemed to have sole power to vote these shares and james tananbaum read more april th   hedge funds  comments nanostring technologies nstg foresite capital growing more bullish jim tananbaums foresite capital has recently increased its stake in nanostring technologies inc nasdaqnstg lifting it to roughly  of the companys common stock whereas it held  shares read more july th   hedge funds news  comments foresite capital betting it all on these four healthcare stocks jim tananbaum’s foresite capital has filed its latest f with the securities and exchange commission for the reporting period of march  disclosing the long positions held in its equity portfolio read more may th   hedge funds news  comments click here to see all news hedge fund resource center how to beat the market by  percentage points why track hedge funds download a free edition why you should dump your hedge funds  things you didnt know about hedge funds billionaire hedge funds warren buffett berkshire hathaway  david einhorn greenlight capital  george soros soros fund management  t boone pickens bp capital  jim simons renaissance technologies  leon cooperman omega advisors  carl icahn icahn capital lp  steve cohen point asset management  john paulson paulson  co  david tepper appaloosa management lp  home hedge funds markets blog authors about us contact us privacy policy terms of use site map all text and design is copyright  koala guide llc all rights reserved microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft foresite capital fund iii lp  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors foresite capital fund iii lp check out list of companies and businesses related to foresite capital fund iii lp find out foresite capital fund iii lp address and contact details view other people related to foresite capital fund iii lp  coworkers colleagues companions etc address  california street suite  san francisco  ca companies related to foresite capital fund iii lp cikcompany namepositioncompany addressaerie pharmaceuticals inc kit creek road suite  research triangle park aimmune therapeutics inc marina boulevard suite  brisbane intellia therapeutics inc erie street suite  cambridge  foresite capital fund iii lp on the web persons related to foresite capital fund iii lp  aerie pharmaceuticals incnamepositioncityacmp iv llcsan franciscoacmp iv llcsan franciscoacp iv lp owner san franciscoacp iv lpsan franciscomehra anandbridgewatermehra anandbedminstervicente anido jrchief executive officer irvinevicente anido jrchief executive officer bedminsterdavid bondermanfort worthdavid bondermanfort worthlevy brianbedminstereric buatoismenlo parkeric buatoismenlo parkgerald d cagledirector bedminsterkopczynski caseybridgewaterkopczynski caseybedminsterclarus lifesciences ii lp owner cambridgeclarus ventures ii gp lpcambridgeclarus ventures ii llccambridgejanet l conwaybedminsterjames g coulterfort worthjames g coulterfort worthrichard croarkindirector irvineepstein davidresearch triangle parkepstein davidbridgewaterepstein davidbedminstergryska davidbedminstermack davidsan franciscomack davidbridgewatermack davidbedminsterhenner dennisbedminstertoit michael dudirector new yorkgeoffrey m duykdirector geoffrey m duykfort worthgeoffrey m duykfort worthgeoffrey m duykdirector fort worthforesite capital fund ii lpsan franciscoforesite capital management ii llc owner san franciscoforesite capital management iii llcsan francisconicholas galakatoscambridgeduyk geoffreysan franciscoduyk geoffreybridgewaterduyk geoffreybedminstercagle geraldbedminstermurray a goldbergdirector murray a goldbergdirector bedminsterdavid w gryskadirector south san franciscodavid w gryskadirector bedminsterjames healymenlo parkjames healymenlo parkdennis hennercambridgemazzo jamesbedminsterconway janetresearch triangle parkconway janetbridgewaterconway janetbedminsterdaniel janneysan franciscodaniel janneysan franciscocasey c kopczynskichief scientific officer bedminsterbrian levychief medical officer rochesterbrian levychief medical officer bedminsterrobert liptakcambridgedavid henry macksan franciscojames v mazzodirector bedminsterbenjamin f mcgraw iiidirector irvinebenjamin f mcgraw iiibedminsterjulie mchughdirector chadds fordanand mehradirector menlo parkanand mehra owner menlo parkanand mehradirector menlo parkdelong mitchellbridgewaterthomas a mitropresident and coo irvinethomas a mitropresident and coo bedminstergoldberg murraybedminstergoldberg murraybedminsterguy p nohrasan franciscoguy p nohrasan franciscomichael powellmenlo parkmichael powellmenlo parkrubino richardbedminsterrichard j rubinochief financial officer franklin lakesrichard j rubinochief financial officer bedminsternicholas simoncambridgesofinnova management vii llcmenlo parksofinnova management vii llcmenlo parksofinnova venture partners vii l pmenlo parksofinnova venture partners vii l p owner menlo parkmichael steinmetzcambridgejames b tananbaumsan franciscomitro thomasbedminstervan haarlem thomasbridgewatervan haarlem thomasbedminstertpg group holdings sbs advisors inc fort worthtpg group holdings sbs advisors inc owner fort worthanido vicentebedminsterkurt wheelercambridgepersons related to foresite capital fund iii lp  aimmune therapeutics incnamepositioncitydaniel c md adelmanchief medical officer south san franciscosusan e barrowcliffegeneral manager europe brisbanegregory behardirector cambridgeeric bjerkholtchief financial officer palo altowalser bryansan mateowarren l desouzachief financial officer brisbanestephen george dillypresident and ceo alamedarobert myles elfontchief medical officer brisbanepatrick g enrightdirector burlingamekathryn e falbergdirector rockvilleforesite capital fund ii lpsan franciscoforesite capital management ii llc owner san franciscoforesite capital management iii llcsan franciscomark t iwickidirector marlboroughtananbaum jamessan franciscoanthony yun joonkyoosan mateojeffrey h knappchief operating officer fremontlongitude capital partners ii llc owner menlo parklongitude venture partners ii lpmenlo parkmark mcdadedirector nestle health science us holdings incnorwalksa nestlevevey switzerlandnimco us incnorwalkenright patrickmenlo parkhoward v raffbrisbanemary m rozenmansee remarks brisbanestacey denenberg seltzerdirector brisbanedouglas t sheehysee remarks redwood cityseltzer staceynew yorkdilly jr stephensan mateobakker juliet tammenomsmenlo parkjames b tananbaumsan franciscocolunga victorsan mateopersons related to foresite capital fund iii lp  intellia therapeutics incnamepositioncityatlas venture associates ix lp owner cambridgeatlas venture associates ix llccambridgeatlas venture fund ix lp owner cambridgebaker bros advisors gp llcnew yorkbaker bros advisors llc new yorkfelix bakerjulian bakerthomas m barnessvp rd extellia cambridgegraeme bellevp chief financial officer palo altonessan berminghampresident  ceo cambridgecaribou biosciences incberkeleycaribou therapeutics holdco llc owner berkeleygordon carlcambridgecaroline dorsadirector whitehouse stationforesite capital management iii llcsan franciscojean francois formeladirector fullerton management pte ltdsingaporecarl l gordondirector new yorkrachel e haurwitzdirector cambridgenicole heifnersvp accounting cambridgesamuel d isalyformela jeanfrancoiscambridgeleonard johncambridgerivera josecambridgeperry a karsendirector rockvillejohn m leonardevp rd north chicagodavid v morrisseysvp platform  delivery tech cambridgebermingham nessancambridgeag novartisch baselnovartis institutes for biomedical research inc owner cambridgeorbimed advisors llcdirector orbimed capital gp v llcnew yorkorbimed global healthcare gp llcnew yorkhaurwitz rachelcambridgejose e riveraevp general counsel  ops cambridgemoncef slaouidirector cambridgesapna srivastavacedar knollsjames b tananbaumsan franciscotemasek holdings ltd owner singaporetemasek life sciences private ltdsingaporetls beta pte ltdsingaporefrank verwieldirector brisbane foresite capital fund iii lp top holdings whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active foresite capital fund iii lp • san francisco ca how do i update this listing foresite capital fund iii is based out of san francisco whalewisdom has at least  dg filings in our database for foresite capital fund iii the firm last filed a form d notice of exempt offering of securities on  the filing was for a pooled investment fund other investment fund the notice included securities offered of pooled investment fund interests summary dg insider form  form d  create email alert × email notification log in or signup to see more advanced email alert options such as selecting any type of sec form multiple filers or classes of filers and much more or to simply have an email sent to you whenever we receive a new f filing from foresite capital fund iii lp enter your email address below and choose submit your email cancel contact info foresite capital fund iii lp  montgomery street san francisco ca     business phone  recent sec filings  filed on   filed on  sc g filed on  sc g filed on  sc ga filed on  sc ga filed on  sc g filed on  sc g filed on  a filed on  a filed on  current dg holdings stock sector shares held market value rank source source date orexigen therapeutics inc orex health care    g  unknown unknown    g  alder biopharm aldr health care    g  achaogen inc akao health care    g  verona pharma plc ads vrna   g  schedule d and g events since  subscription required form   nonderivative insider transactions since  loading form d filings form d is a form to be used to file a notice of an exempt offering of securities with the securities and exchange commission form d contains basic information about the offering and the company form d filings filing date form type industry group securities offered total offering amount total amount sold total remaining  d pooled investment fund other investment fund pooled investment fund interests    other issuers in filings name address no other issuers related parties included in filings name address relationship james b tananbaum subscription required executive officer elevate your investments try it for free